Bio-Techne Shareholders Greenlight $12B Merck KGaA Acquisition
Event summary
- Bio-Techne shareholders approved the $12B acquisition by Merck KGaA on September 23, 2026.
- The transaction is expected to close by late 2026 or early 2027, pending remaining regulatory approvals.
- Bio-Techne generated over $1.2B in net sales in fiscal year 2025.
- The combined entity will support customers across the full spectrum of life science workflows.
The big picture
The acquisition marks a significant consolidation in the life sciences tools and diagnostics sector. Merck KGaA is expanding its capabilities in reagents, analytical instruments, and precision diagnostics, while Bio-Techne shareholders gain immediate cash value. The deal reflects broader industry trends toward vertical integration and end-to-end solutions for research and clinical applications.
What we're watching
- Integration Challenges
- How Merck KGaA will integrate Bio-Techne's operations into its existing structure.
- Regulatory Approvals
- The pace at which remaining regulatory approvals will be obtained.
- Market Positioning
- Whether the combined entity can effectively compete across the full spectrum of life science workflows.
Related topics